{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:59:35Z","timestamp":1774609175197,"version":"3.50.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01AR072129"],"award-info":[{"award-number":["K01AR072129"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["UM-SBDRC 1P30AR075043"],"award-info":[{"award-number":["UM-SBDRC 1P30AR075043"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taubman Institute Innovation Project"},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010236","name":"Babcock Memorial Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010236","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Precision Health Scholars Award from the University of Michigan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Drug\u2013drug interactions (DDIs) can result in adverse and potentially life-threatening health consequences; however, it is challenging to predict potential DDIs in advance. We introduce a new computational approach to comprehensively assess the drug pairs which may be involved in specific DDI types by combining information from large-scale gene expression (984 transcriptomic datasets), molecular structure (2159 drugs), and medical claims (150 million patients).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Features were integrated using ensemble machine learning techniques, and we evaluated the DDIs predicted with a large hospital-based medical records dataset. Our pipeline integrates information from &amp;gt;30 different resources, including &amp;gt;10\u00a0000 drugs and &amp;gt;1.7 million drug\u2013gene pairs. We applied our technique to predict interactions between 37\u00a0611 drug pairs used to treat psoriasis and its comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our approach achieves &amp;gt;0.9 area under the receiver operator curve (AUROC) for differentiating 11\u00a0861 known DDIs from 25\u00a0750 non-DDI drug pairs. Significantly, we demonstrate that the novel DDIs we predict can be confirmed through independent data sources and supported using clinical medical records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>By applying machine learning and taking advantage of molecular, genomic, and health record data, we are able to accurately predict potential new DDIs that can have an impact on public health.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jamia\/ocaa335","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T20:22:05Z","timestamp":1607977325000},"page":"1159-1167","source":"Crossref","is-referenced-by-count":13,"title":["Advancement\u00a0in predicting interactions between drugs used to treat psoriasis and its comorbidities by integrating molecular and clinical resources"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6174-9002","authenticated-orcid":false,"given":"Matthew T","family":"Patrick","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Redina","family":"Bardhi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"School of Medicine, Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpana","family":"Raja","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"Morgridge Institute for Research, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-5722","authenticated-orcid":false,"given":"Lam C","family":"Tsoi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"issue":"5","key":"2021061318593018500_ocaa335-B1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0190-9622(89)70286-3","article-title":"Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate","volume":"21","author":"Krochmal","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2021061318593018500_ocaa335-B2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000251167","article-title":"Dermatopharmacology of salicylic acid. III. Topical contra-inflammatory effect of salicylic acid and other drugs in animal experiments","volume":"152","author":"Weirich","year":"1976","journal-title":"Dermatologica"},{"issue":"5","key":"2021061318593018500_ocaa335-B3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pds.3592","article-title":"Hospital admissions\/visits associated with drug\u2013drug interactions: a systematic review and meta-analysis","volume":"23","author":"Dechanont","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"2021061318593018500_ocaa335-B4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/imj.13404","article-title":"Life-threatening drug interactions: what the physician needs to know","volume":"47","author":"Day","year":"2017","journal-title":"Intern Med J"},{"issue":"3","key":"2021061318593018500_ocaa335-B5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2013.01.006","article-title":"Informatics confronts drug\u2013drug interactions","volume":"34","author":"Percha","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"2021061318593018500_ocaa335-B6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/pds.1351","article-title":"Hospitalisations and emergency department visits due to drug\u2013drug interactions: a literature review","volume":"16","author":"Becker","year":"2007","journal-title":"Pharmacoepidem Drug Saf"},{"issue":"9836","key":"2021061318593018500_ocaa335-B7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"2021061318593018500_ocaa335-B8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2021061318593018500_ocaa335-B9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamainternmed.2015.8581","article-title":"Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011","volume":"176","author":"Qato","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2021061318593018500_ocaa335-B10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12889-019-8123-0","article-title":"Neighborhood socioeconomic disadvantage is associated with multimorbidity in a geographically defined community","volume":"20","author":"Chamberlain","year":"2020","journal-title":"BMC Public Health"},{"issue":"1","key":"2021061318593018500_ocaa335-B11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12913-017-2793-z","article-title":"Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study","volume":"17","author":"Castioni","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"13","key":"2021061318593018500_ocaa335-B12","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.31389","article-title":"Polypharmacy and patterns of prescription medication use among cancer survivors","volume":"124","author":"Murphy","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"2021061318593018500_ocaa335-B13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","article-title":"The rising tide of polypharmacy and drug\u2013drug interactions: population database analysis 1995-2010","volume":"13","author":"Guthrie","year":"2015","journal-title":"BMC Med"},{"key":"2021061318593018500_ocaa335-B14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fphar.2020.00326","article-title":"An increasing trend in the prevalence of polypharmacy in Sweden: a nationwide register-based study","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"2021061318593018500_ocaa335-B15","doi-asserted-by":"crossref","first-page":"e0214240","DOI":"10.1371\/journal.pone.0214240","article-title":"Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States","volume":"14","author":"Oktora","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"2021061318593018500_ocaa335-B16","doi-asserted-by":"crossref","first-page":"e0212046","DOI":"10.1371\/journal.pone.0212046","article-title":"Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015","volume":"14","author":"van den Akker","year":"2019","journal-title":"PLoS One"},{"key":"2021061318593018500_ocaa335-B17","year":"2019"},{"issue":"6","key":"2021061318593018500_ocaa335-B18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2021061318593018500_ocaa335-B19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2021061318593018500_ocaa335-B20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2021061318593018500_ocaa335-B21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1208\/s12248-014-9637-0","article-title":"Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug\u2013drug interaction implications","volume":"16","author":"Wang","year":"2014","journal-title":"AAPS J"},{"issue":"1\u20132","key":"2021061318593018500_ocaa335-B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bdd.2212","article-title":"In vitro and in vivo methods to assess pharmacokinetic drug\u2013drug interactions in drug discovery and development","volume":"41","author":"Lu","year":"2020","journal-title":"Biopharm Drug Dispos"},{"issue":"10","key":"2021061318593018500_ocaa335-B23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vivo drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2021061318593018500_ocaa335-B24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jid.2018.09.018","article-title":"Drug repurposing prediction for immune-mediated cutaneous diseases using a word-embedding-based machine learning approach","volume":"139","author":"Patrick","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2021061318593018500_ocaa335-B25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jbi.2015.04.006","article-title":"Toward a complete dataset of drug\u2013drug interaction information from publicly available sources","volume":"55","author":"Ayvaz","year":"2015","journal-title":"J Biomed Inform"},{"issue":"5","key":"2021061318593018500_ocaa335-B26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jbi.2013.07.011","article-title":"The DDI corpus: an annotated corpus with pharmacological substances and drug\u2013drug interactions","volume":"46","author":"Herrero-Zazo","year":"2013","journal-title":"J Biomed Inform"},{"issue":"suppl_1","key":"2021061318593018500_ocaa335-B27","doi-asserted-by":"crossref","first-page":"D237","DOI":"10.1093\/nar\/gkp970","article-title":"SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions","volume":"38","author":"Preissner","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2021061318593018500_ocaa335-B28","doi-asserted-by":"crossref","first-page":"e0173548","DOI":"10.1371\/journal.pone.0173548","article-title":"Characterization of the mechanism of drug\u2013drug interactions from PubMed using MeSH terms","volume":"12","author":"Lu","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"2021061318593018500_ocaa335-B29","doi-asserted-by":"crossref","first-page":"e0122199","DOI":"10.1371\/journal.pone.0122199","article-title":"Extraction of pharmacokinetic evidence of drug\u2013drug interactions from the literature","volume":"10","author":"Kolchinsky","year":"2015","journal-title":"PLoS One"},{"key":"2021061318593018500_ocaa335-B30","first-page":"216","article-title":"Extracting drug\u2013drug interaction articles from MEDLINE to improve the content of drug databases","author":"Duda","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"issue":"2","key":"2021061318593018500_ocaa335-B31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cpt.914","article-title":"Translational high-dimensional drug interaction discovery and validation using health record databases and pharmacokinetics models","volume":"103","author":"Chiang","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2021061318593018500_ocaa335-B32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/amiajnl-2013-001612","article-title":"Mining clinical text for signals of adverse drug\u2013drug interactions","volume":"21","author":"Iyer","year":"2014","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"2021061318593018500_ocaa335-B33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40264-015-0352-2","article-title":"Feasibility of prioritizing drug\u2013drug-event associations found in electronic health records","volume":"39","author":"Banda","year":"2016","journal-title":"Drug Saf"},{"issue":"5","key":"2021061318593018500_ocaa335-B34","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1109\/JBHI.2018.2874533","article-title":"Mining directional drug interaction effects on myopathy using the FAERS Database","volume":"23","author":"Chasioti","year":"2019","journal-title":"IEEE J Biomed Health Inform"},{"issue":"S2","key":"2021061318593018500_ocaa335-B35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12911-020-1053-z","article-title":"Mining and visualizing high-order directional drug interaction effects using the FAERS database","volume":"20","author":"Yao","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"2021061318593018500_ocaa335-B36","first-page":"1","article-title":"A modified skip-gram algorithm for extracting drug\u2013drug interactions from AERS Reports","volume":"2020","author":"Wang","year":"2020","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"2021061318593018500_ocaa335-B37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/amiajnl-2011-000214","article-title":"A novel signal detection algorithm for identifying hidden drug\u2013drug interactions in adverse event reports","volume":"19","author":"Tatonetti","year":"2012","journal-title":"J Am Med Inform Assoc"},{"issue":"18","key":"2021061318593018500_ocaa335-B38","doi-asserted-by":"crossref","first-page":"E4304","DOI":"10.1073\/pnas.1803294115","article-title":"Deep learning improves prediction of drug\u2013drug and drug\u2013food interactions","volume":"115","author":"Ryu","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2021061318593018500_ocaa335-B39","doi-asserted-by":"crossref","first-page":"e58321","DOI":"10.1371\/journal.pone.0058321","article-title":"Detection of drug\u2013drug interactions by modeling interaction profile fingerprints","volume":"8","author":"Vilar","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"2021061318593018500_ocaa335-B40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nbt1338","article-title":"Drug-target network","volume":"25","author":"Yildirim","year":"2007","journal-title":"Nat Biotechnol"},{"key":"2021061318593018500_ocaa335-B41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jbi.2017.04.021","article-title":"Computational prediction of drug\u2013drug interactions based on drugs functional similarities","volume":"70","author":"Ferdousi","year":"2017","journal-title":"J Biomed Inform"},{"issue":"3","key":"2021061318593018500_ocaa335-B42","doi-asserted-by":"crossref","first-page":"e1002998","DOI":"10.1371\/journal.pcbi.1002998","article-title":"Systematic prediction of pharmacodynamic drug\u2013drug interactions through protein-protein-interaction network","volume":"9","author":"Huang","year":"2013","journal-title":"PLoS Comput Biol"},{"issue":"10","key":"2021061318593018500_ocaa335-B43","doi-asserted-by":"crossref","first-page":"e0140816","DOI":"10.1371\/journal.pone.0140816","article-title":"Predicting pharmacodynamic drug\u2013drug interactions through signaling propagation interference on protein\u2013protein interaction networks","volume":"10","author":"Park","year":"2015","journal-title":"PLoS One"},{"issue":"S1","key":"2021061318593018500_ocaa335-B44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12864-018-5370-x","article-title":"Gene2vec: distributed representation of genes based on co-expression","volume":"20","author":"Du","year":"2019","journal-title":"BMC Genomics"},{"issue":"3","key":"2021061318593018500_ocaa335-B45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/jamiaopen\/ooaa040","article-title":"Using indication embeddings to represent patient health for drug safety studies","volume":"3","author":"Melamed","year":"2020","journal-title":"JAMIA Open"},{"issue":"D1","key":"2021061318593018500_ocaa335-B46","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"2021061318593018500_ocaa335-B47","doi-asserted-by":"crossref","first-page":"D267","DOI":"10.1093\/nar\/gkh061","article-title":"The Unified Medical Language System (UMLS): integrating biomedical terminology","volume":"32","author":"Bodenreider","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2021061318593018500_ocaa335-B48","doi-asserted-by":"crossref","first-page":"e0194295","DOI":"10.1371\/journal.pone.0194295","article-title":"Trends in warfarin use and its associations with thromboembolic and bleeding rates in a population with atrial fibrillation between 1996 and 2011","volume":"13","author":"Hansen","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"2021061318593018500_ocaa335-B49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4314\/njm.v19i1.54216","article-title":"The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study","volume":"19","author":"Naseri","year":"2010","journal-title":"Niger J Med"},{"issue":"3","key":"2021061318593018500_ocaa335-B50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaad.2007.05.040","article-title":"Efficacy of simvastatin in plaque psoriasis: a pilot study","volume":"57","author":"Shirinsky","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2021061318593018500_ocaa335-B51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3889\/oamjms.2019.060","article-title":"Efficacy of adding oral simvastatin to topical therapy for treatment of psoriasis: the Vietnamese experience","volume":"7","author":"Trong","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"issue":"S38","key":"2021061318593018500_ocaa335-B52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1288\/00005537-198509010-00001","article-title":"Furosemide ototoxicity: clinical and experimental aspects","volume":"95","author":"Rybak","year":"1985","journal-title":"Laryngoscope"},{"issue":"11","key":"2021061318593018500_ocaa335-B53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00535-005-1687-8","article-title":"Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review","volume":"40","author":"Hojo","year":"2005","journal-title":"J Gastroenterol"},{"issue":"2","key":"2021061318593018500_ocaa335-B54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/cd18-0012","article-title":"Good to know: factors affecting blood glucose","volume":"36","year":"2018","journal-title":"Clin Diabetes"},{"issue":"4","key":"2021061318593018500_ocaa335-B55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/14740338.2020.1722640","article-title":"Safety considerations with combination therapies for psoriasis","volume":"19","author":"Nakamura","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2021061318593018500_ocaa335-B56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00228-017-2357-5","article-title":"Drug\u2013drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis","volume":"74","author":"Zheng","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2021061318593018500_ocaa335-B57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40886-018-0075-z","article-title":"Potential drug-to-drug interactions: a cross-sectional study among older patients discharged from hospital to home care","volume":"4","author":"Olsen","year":"2018","journal-title":"Saf Health"},{"issue":"1","key":"2021061318593018500_ocaa335-B58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12911-017-0430-8","article-title":"Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system","volume":"17","author":"Ancker","year":"2017","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"2021061318593018500_ocaa335-B59","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jamia\/ocaa034","article-title":"High-priority drug\u2013drug interaction clinical decision support overrides in a newly implemented commercial computerized provider order-entry system: override appropriateness and adverse drug events","volume":"27","author":"Edrees","year":"2020","journal-title":"J Am Med Inform Assoc"},{"issue":"8","key":"2021061318593018500_ocaa335-B60","doi-asserted-by":"crossref","first-page":"e12992","DOI":"10.1111\/ijcp.12992","article-title":"Goodbye Physicians\u2019 Desk Reference, hello Prescribers\u2019 Desk Reference!","volume":"71","author":"Citrome","year":"2017","journal-title":"Int J Clin Pract"},{"issue":"15","key":"2021061318593018500_ocaa335-B61","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1093\/bioinformatics\/btaa501","article-title":"A multimodal deep learning framework for predicting drug\u2013drug interaction events","volume":"36","author":"Deng","year":"2020","journal-title":"Bioinformatics"},{"issue":"S19","key":"2021061318593018500_ocaa335-B62","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12859-019-3214-6","article-title":"DDI-PULearn: a positive-unlabeled learning method for large-scale prediction of drug\u2013drug interactions","volume":"20","author":"Zheng","year":"2019","journal-title":"BMC Bioinformatics"},{"issue":"12","key":"2021061318593018500_ocaa335-B63","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23123193","article-title":"Adverse drug reaction predictions using stacking deep heterogeneous information network embedding approach","volume":"23","author":"Hu","year":"2018","journal-title":"Molecules"}],"container-title":["Journal of the American Medical Informatics Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/28\/6\/1159\/38615421\/ocaa335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/28\/6\/1159\/38615421\/ocaa335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T19:01:01Z","timestamp":1623610861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamia\/article\/28\/6\/1159\/6129362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,5]]},"published-print":{"date-parts":[[2021,6,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jamia\/ocaa335","relation":{},"ISSN":["1527-974X"],"issn-type":[{"value":"1527-974X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,2,5]]}}}